The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson’s disease
Author:
- 20 June 2010
- journal article
- review article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 117 (7) , 837-846
Abstract
Long-term treatment of Parkinson’s disease (PD) with dopaminergic therapy is associated with a re-emergence of PD symptoms, referred to as wearing-off. Signs of wearing-off encompass motor symptoms, such as slowness of movement and stiffness, and non-motor symptoms, including anxiety and fatigue. Both motor and non-motor symptoms impact significantly on the function and quality of life of PD patients. Early detection and management of wearing-off has been shown to improve patient symptoms; however, identification of wearing-off, particularly the non-motor symptoms, is hampered by a lack of patient education, awareness, patient–physician communication, and limited time for evaluation. Several questionnaires have been developed to aid the detection of wearing-off. This review investigates the development and use of the Wearing-Off Questionnaires (WOQ-32, WOQ-19, and WOQ-9), as well as their sensitivity and specificity in identifying wearing-off. The manuscript also provides an overview of the motor and non-motor signs of wearing-off and highlights the available treatment strategies for managing this potentially debilitating phenomenon.Keywords
This publication has 50 references indexed in Scilit:
- Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week studyJournal of Neural Transmission, 2009
- The Patient Card Questionnaire to Identify Wearing-off in Parkinson DiseaseClinical Neuropharmacology, 2007
- End-of-dose Wearing Off in Parkinson DiseaseClinical Neuropharmacology, 2006
- Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society‐European Section (MDS‐ES). Part II: late (complicated) Parkinson's diseaseEuropean Journal of Neurology, 2006
- The levodopa wearing-off phenomenon in Parkinson’s disease: pharmacokinetic considerationsExpert Opinion on Pharmacotherapy, 2006
- Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuationsActa Neurologica Scandinavica, 2005
- Validation of a New Diagnostic Questionnaire for Headache: the Migraine in Primary Care Advisors/Migraine Action Association (MIPCA/MAA) Headache Diagnostic Screening Questionnaire (DSQ)Headache Care, 2004
- Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre studyJournal of Neural Transmission, 2003
- Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnoverAnnals of Neurology, 2001
- Clinical Pharmacokinetics and Pharmacodynamics of SelegilineClinical Pharmacokinetics, 1997